Quantitative Health Sciences

Medicine & Life Sciences

1. Neoplasms 100%
2. Colorectal Neoplasms 99%
3. Cognitive Dysfunction 92%
4. Breast Neoplasms 68%
5. Patient Reported Outcome Measures 63%
6. Mutation 53%
7. Hereditary Nonpolyposis Colorectal Neoplasms 47%
8. Dementia 41%
9. Confidence Intervals 39%
10. Survival 38%
11. Smoking Cessation 37%
12. Trastuzumab 36%
13. Population 36%
14. Radiotherapy 35%
15. Therapeutics 35%
16. Genes 33%
17. Quality of Life 32%
18. Colonic Neoplasms 32%
19. Registries 31%
20. Alzheimer Disease 31%
21. Tobacco 28%
22. Terminology 26%
23. Clinical Trials 25%
24. T-Lymphocytes 25%
25. Ovarian Neoplasms 24%
26. Depression 23%
27. Apolipoprotein E4 23%
28. Radiosurgery 23%
29. Amyloid 22%
30. Primary Myelofibrosis 22%
31. Research Personnel 21%
32. Hemorrhage 20%
33. Odds Ratio 20%
34. Drug Therapy 19%
35. Biomarkers 19%
36. Cognition 19%
37. Genome-Wide Association Study 19%
38. Polycythemia Vera 19%
39. Tobacco Use Cessation 18%
40. Elderly 18%
41. Smokers 18%
42. Non-Small Cell Lung Carcinoma 18%
43. Proton Therapy 17%
44. Smoking 17%
45. Tobacco Products 17%
46. Recurrence 16%
47. Cohort Studies 16%
48. National Cancer Institute (U.S.) 16%
49. Lapatinib 16%
50. Guidelines 15%
51. Tobacco Use Cessation Devices 15%
52. Prostatic Neoplasms 15%
53. Melanoma 15%
54. Germ-Line Mutation 15%
55. human ERBB2 protein 15%
56. Alleles 15%
57. Genome 14%
58. Phenotype 14%
59. Breast 14%
60. Electronic Nicotine Delivery Systems 14%
61. Placebos 14%
62. Health 14%
63. Glioblastoma 14%
64. Anxiety 14%
65. Radiation 14%
66. Immunity 14%
67. Cognitive Aging 13%
68. Anticoagulants 13%
69. Incidence 13%
70. Tobacco Use 13%
71. Barrett Esophagus 13%
72. Hispanic Americans 13%
73. Consensus 13%
74. Adenocarcinoma 13%
75. Prospective Studies 12%
76. Genotype 12%
77. Memory 12%
78. Bupropion 12%
79. INCB018424 12%
80. Symptom Assessment 12%
81. Anti-Inflammatory Agents 11%
82. Brachytherapy 11%
83. Essential Thrombocythemia 11%
84. Veterans 11%
85. 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole 11%
86. Social Networking 11%
87. Pharmaceutical Preparations 11%
88. Endometrial Neoplasms 11%
89. Mortality 11%
90. Genetic Testing 11%
91. Single Nucleotide Polymorphism 11%
92. Fatigue 11%
93. Exercise 10%
94. Pancreatic Neoplasms 10%
95. Randomized Controlled Trials 10%
96. Disease-Free Survival 10%
97. Medical Oncology 10%
98. Microsatellite Instability 10%